Oppenheimer Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $145
Oppenheimer analyst Leland Gershell maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $125 to $145.
Login to comment